Phibro Animal Health Corporation Q2 2026 Earnings Recap

PAHC Q2 2026 February 5, 2026

Phibro Animal Health Corporation reported strong second-quarter results, with a 26% increase in animal health sales and a substantial 41% rise in adjusted EBITDA, reflecting effective integration strategies and robust demand across key sectors.

Earnings Per Share Beat

$0.87 vs $0.69 est.

+26.1% surprise

Revenue Beat

373900000 vs 355636400 est.

+5.1% surprise

Market Reaction

1-Day +21.95%

5-Day +26.46%

30-Day +33.41%

Key Takeaways

Animal health sales surged by 26%, led by a 34% growth in medicated feed additives.
Consolidated sales rose 21% to $373.9 million, with EBITDA reflecting a 41% increase.
Full-year sales and earnings guidance has been raised based on strong momentum and operational performance.
Positive feedback from customers and strong leadership alignment highlight the company’s strategic execution and market position.
Leadership transition slated for July is expected to reinforce momentum and operational excellence.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PAHC on AllInvestView.

Previous Q4 2025